Project Grant R61NS145983
Award Date 6/1/26
Completion Date 5/31/28
Dollars Obligated $1M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Lowell, MA 01854, USA
Similar Awards
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $5.3 million Project Grant to Massachusetts General Hospital on August 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the role of the gut microbiome in individual differences in lumbosacral radicular pain (LSRP) outcomes. The four-year research initiative, concluding July 31, 2029, will develop statistical and machine learning models to examine...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded Massachusetts Institute of Technology a Project Grant valued at $591,122 on August 1, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The grant supports a four-year research initiative (through July 31, 2029) to decode and modulate the emotional component of pain through investigation of autonomic nervous system...
- Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke awarded a $4.04 million Project Grant to the University of Texas at Dallas for a three-year initiative (September 1, 2025 through August 31, 2028) to identify and validate therapeutic targets for chronic pain treatment. The project leverages a CRISPR-based functional genomic screening platform developed by collaborating researchers at the University of Sydney and an extensive human dorsal root ganglion...
- Federal Project Grant Award Summary Function Therapeutics Inc. received a $499,863 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) on September 11, 2025, with a completion date of August 31, 2027. The award supports research and development of parmodulins, a novel class of small molecule therapeutics designed to treat neuropathic pain without abuse potential. The project involves...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded the University of North Carolina at Chapel Hill a $222,758 Project Grant on August 7, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research through July 31, 2027. The award funds a comprehensive neuroscience investigation aimed at delineating how different molecularly defined dorsal root ganglia (DRG) neuron types contribute to pain representation...
- Federal Project Grant Award Summary Award Overview: The National Institute of Neurological Disorders and Stroke (NINDS) awarded Massachusetts General Hospital $9.74M on August 26, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a two-year prospective longitudinal study examining factors associated with vulvodynia pain resolution and persistence. The project, concluding June 30, 2030, will enroll a cohort of 200 women aged 18-45 with vulvodynia—a chronic pain...
- Federal Project Grant Award Summary The University of Massachusetts Medical School received a $479,385 project grant from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective June 1, 2026 through May 30, 2028. This award funds research aimed at investigating platelet-derived growth factor receptor beta (PDGFRB) as a therapeutic target to prevent opioid-induced respiratory depression (OIRD) and overdose deaths. The...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded the University of Massachusetts Medical School a $1.74 million Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning July 15, 2025, with completion targeted for March 31, 2030. This award supports research focused on the discovery and functional characterization of long non-coding RNAs (lncRNAs) in opioid use disorder (OUD) within the context of HIV at single-cell resolution. The...
- This federal Project Grant award for $1,587,553.00 was provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is focused on developing novel 5-HT3 receptor antagonists for the treatment of neuropathic pain. The key objectives are to: 1) use computational drug design approaches to identify novel 5-HT3 receptor antagonist chemotypes with potential for central nervous system (CNS) penetration and...
- Federal Grant Award Summary The National Institute on Drug Abuse (NIDA) awarded The Washington University a $1.96 million Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) effective August 15, 2025, through April 30, 2030. This research award supports a comprehensive investigation into the mesolimbic dopaminergic adaptations underlying altered reward sensitivity in chronic neuropathic pain (CNP). The project addresses a critical clinical gap, as 27–75% of CNP...